Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
According to Cancer Research UK, it 'stimulates the pigment cells in your skin to produce more melanin, and this makes the skin look darker' - and it is illegal to sell and supply in the UK
Gregg, E.W
Moxit Shah Endocrinologist, Ahmedabad If you are looking for expert guidance on: Medical weight loss GLP-1 therapy Tirzepatide (Mounjaro) Semaglutide (Ozempic/Wegovy) Diabetes management Thyroid disorders PCOS Hormonal disorders Book your consultation today
What payers require for Zepbound prior authorization Zepbound PA requirements are typically more stringent: Documented BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity Evidence of lifestyle intervention including documented participation in diet, exercise, and behavioral modification programs (usually for at least 3 to 6 months) Prior medication trials (some plans require documented failure of other weight management medications before approving tirzepatide) Specialist involvement (some plans require referral to or management by a bariatric medicine specialist, endocrinologist, or obesity medicine physician) Ongoing weight monitoring documentation with specific weight loss targets (typically 5% of baseline weight within 3 to 6 months of starting therapy) Patients researching BMI requirements for GLP-1 medications should understand that these thresholds directly correspond to the prior authorization criteria their provider must document
While research into predictors of response is ongoing, there is currently insufficient evidence to recommend routine genetic testing to predict individual responses to semaglutide therapy
